TY - JOUR T1 - Sublingual piroxicam in migraine without aura. AU - Ravishankar,K, AU - Tayade,Himanshu, AU - Mandlik,Rahul, PY - 2011/9/6/entrez PY - 2011/9/6/pubmed PY - 2011/10/1/medline SP - 494 EP - 7 JF - The Journal of the Association of Physicians of India JO - J Assoc Physicians India VL - 59 N2 - OBJECTIVE: The aim of the present study was to compare the analgesic efficacy of a single dose of sublingual piroxicam to that of a placebo during acute attacks of migraine without aura. METHODS: The drug (N = 30) or a placebo (N = 30) was administered, on randomisation and double-blind basis, to 60 patients between 18 and 50 years of age suffering from migraine without aura. The patients were instructed to take a single tablet sublingually [corresponding to piroxicam 40 mg or placebo] and the severity of the painful symptomatology and associated symptoms were evaluated by this study. RESULTS: The patients treated with sublingual piroxicam showed a significant (P < 0.05) decrease in pain intensity 15 minutes after ingestion; they went on to show a further reduction in the 24 hours after drug administration. On the contrary, the group treated with placebo showed a significant reduction of symptoms only after seven hours of observation. Associated symptoms disappeared significantly (P < 0.05) after sublingual piroxicam administration. In 83.3%, the drug resulted in excellent to good response as compared to only 10% in the placebo group. No local and systemic side effects were reported with sublingual piroxicam. CONCLUSIONS: The present study has demonstrated that for the acute management of migraine without aura sublingual piroxicam showed significant analgesic effect with excellent tolerability. SN - 0004-5772 UR - https://www.unboundmedicine.com/medline/citation/21887905/Sublingual_piroxicam_in_migraine_without_aura_ L2 - http://www.diseaseinfosearch.org/result/4811 DB - PRIME DP - Unbound Medicine ER -